

Substitute for form 1449A/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/516,757
		Filing Date	December 4, 2004
		First Named Inventor	Rabussay, Dietmar
		Art Unit	TBA- 1655
		Examiner Name	TBA- Tate
Sheet	1	of	2
Attorney Docket No: GTI-1490-US			

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
	1	3523907	08/11/1970	VRANCKEN et al	
	2	5171568	12/15/1992	BURKE et al	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	3	WO 89/04669	06/01/1989	HOUGHTON et al	
	4	WO 90/11089	10/04/1990	HOUGHTON et al	
	5	WO 90/14436	11/29/1990	HOUGHTON et al	
	6	WO 90/14837	12/13/1990	VAN NEST et al	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					T <sup>2</sup>
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	7	BAER et al, "DNA Sequence and Expression of the B95-8 Epstein Barr Virus Genome," <i>Nature</i> 310:207-211 (1984)			
	8	CHEE et al, "Analysis of the protein-coding content of the sequence of human cytomegaloviruses strain AD169," <i>Curr Top Microbiol Immunol.</i> 154:125-169			
	9	DAVISON et al, "The complete DNA sequence of varicella-zoster virus," <i>J. Gen. Virol.</i> 67:1759-1816 (1986)			
	10	DOE et al, "Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans," <i>Eur. J. Immunol.</i> 24(10):2369-2376 (1994)			
	11	ERICKSON et al, "Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis," <i>J. Immunol.</i> 151:4189-4199 (1993)			
	12	HOUGHTON et al, "Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease," <i>Hepatology</i> 14(2):381-388 (1991)			
	13	JEFFERY et al, "The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique," <i>Pharm Res.</i> 10(3):362-368 (1993)			
	14	KAWAOKA et al, "Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus," <i>Virology</i> 179:759-767 (1990)			
	15	MCGEOCH et al, "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type," <i>J. Gen. Virol.</i> 69:1531-1574 (1988)			
	16	MIZUSHIMA et al, "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> 18(17):5322 (1990)			
	17	MODROW et al, "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions," <i>J. Virology</i> 61:570-578 (1987)			
	18	MORIARTY et al, "Expression of the Hepatitis B Virus Surface Antigen Gene in Cell Culture by Using a Simian Virus 40 Vector," <i>Proc. Natl. Acad. Sci. (USA)</i> 78(4):2606-2610 (1981)			
	19	O'HAGAN et al, "Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles," <i>Vaccine</i> 11:965-969 (1993)			
	20	OGAWA et al, "A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid," <i>Chem. Pharm. Bull.</i> 36:1095-1103 (1988)			
	21	OTT et al, "MF-59—Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines," in POWELL et al, <i>Vaccine Design: The Subunit and Adjuvant Approach</i> Plenum Press, New York pp. 277-296 (1995)			
	22	REMINGTON <i>The Science and Practice of Pharmacy</i> , Mack Publishing Company, Easton, PA, 19 <sup>th</sup> Edition (1995)			

EXAMINER /Christopher Tate/

DATE CONSIDERED 12/14/2009

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R.T./

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: right; font-size: small;">Complete If Known</td> </tr> <tr> <td style="width: 40%;">Application Number</td> <td>10/516,757</td> </tr> <tr> <td>Filing Date</td> <td>December 4, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Rabussay, Dietmar</td> </tr> <tr> <td>Art Unit</td> <td>TBA- 1655</td> </tr> <tr> <td>Examiner Name</td> <td>TBA Tate</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> </table>		Complete If Known		Application Number	10/516,757	Filing Date	December 4, 2004	First Named Inventor	Rabussay, Dietmar	Art Unit	TBA- 1655	Examiner Name	TBA Tate		
Complete If Known																			
Application Number	10/516,757																		
Filing Date	December 4, 2004																		
First Named Inventor	Rabussay, Dietmar																		
Art Unit	TBA- 1655																		
Examiner Name	TBA Tate																		
Sheet	2	of	2	Attorney Docket No: GTI-1490-US															

	23	VAN NEST et al, "Advanced adjuvant formulations for use with recombinant subunit vaccines," in BROWN et al, <i>Vaccines 92, Modern Approaches to New Vaccines</i> Cold Springs Harbor Laboratory Press pp. 57-62 (1992)	
	24	WEBSTER et al, "Antigenic variation among type A influenza viruses," p. 127-168. In: alese et al (ed.), <i>Genetics of influenza viruses</i> . Springer-Verlag, New York	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R.T./

EXAMINER      /Christopher Tate/

DATE CONSIDERED    12/14/2009

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	1 6,757
Filing Date	December 4, 2004
First Named Inventor	Rabussay, Dietmar P.
Group Art Unit	To Be Assigned 1655
Examiner Name	To Be Assigned Tate

Sheet 1 of 1

Attorney Docket No: GTI-1490-US

**US PATENT DOCUMENTS**

Examiner Initials *	Cite No. 1	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US 6,120,493	19 Sep 2000	Hoffman	
	A2.	US 5,810,762	22 Sep 1998	Hofmann	
	A3.	US 5,439,440	08 Aug 1995	Hofmann	
	A4.	US 5,273,525	28 Dec 1993	Hofmann	
	A5.	US 5,128,257	07 Jul 1992	Baer	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. 1	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 2
	A6.	WO 01/07585 A	01 Feb 2001	Regents Univ. of CA		
	A7.	WO 99/22810	14 May 1999	Hisamitsu Pharm. Co.		

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 3
	A8.	BOON, T., "Teaching the immune system to fight cancer," <i>Scientific American</i> 288(3):82-89 (March 1993)	
	A9.	DEV et al., "Medical applications of electroporation," <i>IEEE Transactions on plasma science</i> , 28(1):206-223 (2000)	
	A10.	FEWELL et al., "Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation," <i>Molecular Therapy</i> 3:574-583 (2000)	
	A11.	GLASSPOOL-MALONE et al., "Efficient nonviral cutaneous transfection," <i>Molecular Therapy</i> 2:140-146 (2000)	
	A12.	HOFFMANN et al., "Electroporation therapy of solid tumors," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> 16(6):523-569 (1999)	
	A13.	TOMOV et al., "Are the stainless steel electrodes inert?," <i>Bioelectrochemistry</i> 51(2):207-209 (2000)	
	A14.	ZELPHATI et al., "PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA," <i>Biotechniques</i> 28:304-310; 312-314; 316 (2000)	
	A15.	ZHANG et al., "Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation," <i>Biochim. Biophys. Acta</i> 1572(1):1-9 (2002)	

EXAMINER

/Christopher Tate/

DATE CONSIDERED

12/14/2009

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant to place a check mark here if English language translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R.T./